Multiple myeloma: a model for scientific and clinical progress

Area of Science:

• Hematology
• Oncology
• Cancer Biology

Background:

• Multiple myeloma (MM) serves as a model for studying cancer progression from premalignant monoclonal gammopathy of undetermined significance.
• The pathogenesis of MM involves intricate interactions between plasma cells and their microenvironment, alongside the tumor clone's genetic characteristics.
• MM exhibits significant genetic complexity, including cytogenetic abnormalities and intraclonal heterogeneity, which critically influence patient prognosis.

Purpose of the Study:

• To investigate the mechanisms underlying the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.
• To emphasize the need for improved prognostic tools and minimal residual disease monitoring techniques due to evolving treatment landscapes.
• To explore new therapeutic strategies and emerging drug classes for multiple myeloma.

Main Methods:

• Review of current understanding of multiple myeloma pathogenesis, including cellular interactions and genetic factors.
• Analysis of advancements in treatment modalities for multiple myeloma over the past two decades.
• Exploration of emerging drug classes and potential new therapeutic avenues.

Main Results:

• The outcome for MM patients has significantly improved due to high-dose therapy, stem cell transplantation, proteasome inhibitors, and immunomodulatory agents.
• Emerging therapies include novel proteasome inhibitors, immunomodulators, monoclonal antibodies, and other targeted agents.
• Revisiting diagnostic criteria for early MM and enabling early intervention are crucial for future treatment strategies.

Conclusions:

• Multiple myeloma is a complex disease requiring personalized treatment approaches.
• Continued research into MM pathogenesis and the development of novel therapies are essential for improving patient outcomes and striving for a cure.
• Balancing treatment efficacy, toxicity, and cost is paramount in the ongoing fight against multiple myeloma.